Psychosis in bipolar disorder: Does it represent a more “severe” illness? by Burton, Cynthia Z et al.
18  |   wileyonlinelibrary.com/journal/bdi Bipolar Disorders. 2018;20:18–26.© 2017 John Wiley & Sons A/S. 
Published by John Wiley & Sons Ltd
Received: 31 March 2017  |  Accepted: 26 June 2017
DOI: 10.1111/bdi.12527
O R I G I N A L  A R T I C L E
Psychosis in bipolar disorder: Does it represent a more “severe” 
illness?
Cynthia Z Burton1 | Kelly A Ryan1 | Masoud Kamali1,2 | David F Marshall1 |  
Gloria Harrington1 | Melvin G McInnis1 | Ivy F Tso1
1Department of Psychiatry, University of 
Michigan, Ann Arbor, MI, USA
2Massachusetts General Hospital, Boston, 
MA, USA
Correspondence
Cynthia Burton, 4250 Plymouth Road, Ann 
Arbor, MI, USA
Email: czburton@med.umich.edu
Funding information
National Institutes of Health, Grant/Award 
Number: 5KL2TR000434; National Institute 
of Mental Health, Grant/Award Number: 
K23MH108823; Heinz C. Prechter Bipolar 
Research Fund; Richard Tam Foundation
Objectives: Although there is a common clinical assumption that bipolar disorder with 
psychotic features reflects greater severity than bipolar disorder without psychosis, 
the existing empirical literature is mixed. This study investigated the phenomenology 
of psychosis as well as demographic, clinical, functional, and neuropsychological fea‐
tures in a large, cross- sectional sample of participants with bipolar disorder divided by 
history of psychosis.
Methods: In a large single study, 168 affective- only bipolar disorder (BP- A) partici‐
pants and 213 bipolar disorder with a history of psychosis (BP- P) participants com‐
pleted a comprehensive clinical diagnostic interview and neuropsychological testing. t 
tests, chi- square tests, and Bayes factors were used to investigate group differences 
or lack thereof.
Results: The prevalence of psychosis in this sample (53%) was similar to published re‐
ports. Nearly half of BP- P participants experienced grandiose delusions, and relatively 
few endorsed “first- rank” hallucinations of running commentary or two or more voices 
conversing. There were no demographic or neuropsychological differences between 
groups. BP- A participants experienced greater chronicity of affective symptoms and a 
greater degree of rapid cycling than BP- P participants; there were no other clinical 
differences between groups.
Conclusions: Overall, these results contradict the conventional notion that bipolar dis‐
order with psychotic features represents a more severe illness than bipolar disorder 
without a history of psychosis. The presence of psychosis does not appear to be as‐
sociated with poorer clinical/functional outcome or suggest a greater degree of neu‐
ropsychological impairment; conversely, the absence of psychosis was associated with 
affective chronicity and rapid cycling. Nosological and treatment implications are 
discussed.
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1  | INTRODUCTION
Psychosis, generally defined as the occurrence of hallucinations or de‐
lusions, is a common feature across numerous psychiatric disorders.1–3 
An exemplar psychotic illness is schizophrenia, which is often associated 
with chronic psychosis symptoms and poor psychosocial outcome. 
Psychosis is also an especially prevalent phenotype in bipolar disorder 
(BP), with greater than half of all individuals diagnosed with BP experi‐
encing psychotic mood episodes in their lifetime.4 Consequently, there 
is a common clinical assumption that BP with psychosis represents a 
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more “severe” form of illness than BP without psychosis, and may re‐
semble the clinical and functional deterioration commonly seen in pri‐
mary psychotic disorders. This notion is supported by the Diagnostic 
and Statistical Manual of Mental Disorders,5,6 where the presence of 
psychosis automatically changes an otherwise hypomanic episode to 
a manic episode (and a corresponding bipolar I disorder diagnosis). 
Overlapping genetic findings between BP and schizophrenia have also 
contributed to this assumption,7,8 although low odds ratios reported 
limit the conclusiveness of these results. The empirical literature in this 
area is mixed. Relatively few studies have examined demographic, clin‐
ical, and neuropsychological differences among individuals diagnosed 
with affective- only BP (BP- A) and psychotic BP (BP- P), with few con‐
clusive findings. The question of whether the presence of psychosis in 
BP truly represents a more “severe” subtype of illness, as is currently 
assumed, has important nosological and treatment implications. This 
study investigated the phenomenology of psychotic features as well as 
clinical, functional, and neuropsychological differences between BP- A 
and BP- P participants in a large cross- sectional sample.
Regarding demographic, functional, and clinical differences, a 2010 
meta- analysis revealed that, compared with BP- A, BP- P participants 
had more inpatient hospitalizations, younger age of onset, and fewer 
years of education, although there were no significant differences for 
age, gender, or duration of illness.9 A later study with 199 BP partic‐
ipants found that BP- P participants had a shorter duration of illness, 
fewer episodes of elevated mood, fewer current depressive symp‐
toms, and lower current functioning scores than BP- A participants.10 
Other studies have failed to find any differences between BP- A and 
BP- P participants. For example, Keck et al.11 enrolled 352 participants 
with bipolar I disorder—the largest published study before this present 
study—and explored a range of variables including age, gender, ethnic‐
ity, education, psychosocial support, income, vocational status, illness 
characteristics like the presence of mixed episodes or rapid cycling, 
age of treatment initiation, history of suicide attempts, and presence 
of comorbid disorders, and found no significant differences between 
BP- P and BP- A groups. They did find that BP- P participants were less 
likely to have a first- degree relative diagnosed with BP.11
As for neuropsychological functioning, several studies have com‐
pared neuropsychological performance between BP- A and BP- P par‐
ticipants. A 2010 meta- analysis consolidated this literature, comprising 
11 published studies including over 700 participants, and reporting a 
small but significant difference between BP- P individuals and BP- A 
individuals in global cognition (Cohen’s d=0.22).9 BP- P individuals also 
performed more poorly in four out of six neuropsychological domains, 
including planning/reasoning (d=0.31), working memory (d=0.28), 
verbal memory (d=0.39), and processing speed (0.20); there were no 
differences in attention or visual memory.9 However, a more recent 
study reported that BP- P participants performed more poorly than 
BP- A participants on a measure of semantic fluency, although history 
of psychosis was not associated with poorer performance on measures 
of verbal learning and memory, working memory, processing speed, 
response inhibition, or phonetic fluency.10 Additional recent findings 
have supported a lack of neuropsychological differences between 
those with and without a history of psychosis among first- treatment 
bipolar I disorder individuals12 as well as euthymic outpatients with a 
range of bipolar disorder diagnoses.13
Given the conflicting findings and relatively small effects in the 
published literature to date, further examination of the presence of 
psychosis among people diagnosed with BP and whether it is associ‐
ated with greater clinical, functional (e.g., occupational or social dys‐
function), or neuropsychological impairment is warranted. Clarification 
of whether BP with psychosis indeed reflects a greater degree of se‐
verity is an important inquiry in terms of nosology and treatment. For 
example, as the field of psychiatry moves toward dimensional symp‐
tom and functional descriptions rather than categorical classification, 
it will be helpful to have a better understanding of what features 
characterize “bipolar- spectrum” or “psychosis- spectrum” illnesses and 
whether they produce different targets for intervention. Recognizing 
similarities and differences between BP with and without psychosis is 
also important for diagnostic classification and prognostic value. This 
knowledge may inform providers’ clinical decision- making; if the pres‐
ence of psychosis is associated with poorer functioning, for example, 
providers may wish to target psychotic symptoms separately or more 
aggressively than mood symptoms. To address these questions, this 
study investigated the phenomenology of psychosis as well as demo‐
graphic, clinical, functional, and neuropsychological characteristics 
among a large cross- sectional sample of participants with BP, divided 
by history of psychosis.
2  | MATERIALS AND METHODS
2.1 | Participants
Participants were enrolled in the University of Michigan Prechter 
Longitudinal Study of Bipolar Disorder, an institutional review board 
(IRBMED) - approved study which broadly aims to assess biological 
and environmental factors associated with clinical outcome in a large 
sample of people diagnosed with BP through longitudinal, naturalistic 
follow- up. Between February 2006 and December 2010, 405 individ‐
uals diagnosed with BP enrolled in the study; 170 were characterized 
as having “affective only” BP (BP- A), 213 had a history of psychosis 
(BP- P), and 22 had an uncertain history of psychosis and were ex‐
cluded from further analyses.
2.2 | Procedures
Potential participants were referred by treating clinicians or self- 
referral in response to recruitment advertising in clinic or commu‐
nity settings (including the University of Michigan Human Research 
Recruiting Registry, office bulletin boards, newspapers, websites, and 
community outreach events). Inclusion criteria were: (i) age ≥18 years, 
(ii) diagnosis of BP (including Bipolar I Disorder [BP I], Bipolar II 
Disorder [BP II], and Bipolar Disorder Not Otherwise Specified [BP 
NOS]), and (iii) willingness to participate in a longitudinal study. 
Exclusion criteria consisted of: (i) active/current substance depend‐
ence, (ii) medical illness associated with depression including, but not 
limited to, terminal cancers, Cushing’s disease, and stroke, (iii) history 
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of severe head injury or other neurological injury, and (iv) substan‐
tial intellectual impairment (intelligence quotient [IQ]<70). Following 
provision of written informed consent, participants completed a com‐
prehensive assessment consisting of a clinical diagnostic interview 
(Diagnostic Interview for Genetic Studies [DIGS]14), and neuropsy‐
chological testing. Participants’ diagnoses were confirmed via medical 
record review if available, and followed by best estimate consensus 
regarding diagnosis reached by two independent MD- or PhD- level 
clinicians. The presence of any psychosis during an affective episode 
was rated from information collected on the DIGS as 0 (never), 1 (dur‐
ing depression only), 2 (during mania only), 3 (during both), or 9 (uncer‐
tain about presence of psychosis). BP participants rated as 0 (never) 
were included in the BP- A group, and those rated as 1, 2, or 3 were 
included in the BP- P group. BP- A participants included 94 individuals 
diagnosed with BP I, 52 individuals diagnosed with BP II, and 22 indi‐
viduals with BP NOS. The BP- P group was comprised of 200 individu‐
als with BP I, 10 individuals with BP II, and three individuals with BP 
NOS. Those who had psychosis outside an affective episode were not 
diagnosed with BP and were not included in this study.
2.3 | Measures
The DIGS is a clinical interview designed to assess major mood and 
psychotic disorders and related conditions; it also includes a detailed 
assessment of the course and chronology of symptoms and therefore 
yields an abundance of clinical information.14 Specific clinical variables 
used in the analyses were derived from the DIGS and included history 
of mixed episodes, history of suicidality, substance abuse chronicity, 
functional impact of illness, first- degree relative with BP, chronicity 
of affective disorder, and presence of rapid cycling. Ratings that were 
classified as “uncertain” were recoded as missing data. In addition to 
the DIGS, participants completed numerous neuropsychological meas‐
ures; these variables were subjected to standard data reduction tech‐
niques using confirmatory factor analysis and described elsewhere.15 
The resulting factors included auditory memory, visual memory, fine 
motor skill, emotion processing, and four domains of executive func‐
tioning: verbal fluency and processing speed, processing speed with 
interference resolution, conceptual reasoning and set- shifting, and 
inhibitory control. These neuropsychological domains and their con‐
stituent measures are summarized in Figure 1.
2.4 | Analyses
Participants with BP and no history of psychosis (BP- A) were com‐
pared with participants with BP and a history of psychosis (BP- P) via 
independent- samples t tests or chi- square tests for demographic, 
clinical, and neuropsychological variables. The original sample in‐
cluded 170 BP- A participants and 213 BP- P participants; these groups 
were found to significantly differ on duration of illness (BP- A, mean 
duration 25.2 years [standard deviation (SD)=13.8 years] vs BP- P, 
22.4 years [SD=13.0 years]; t=2.06; df=379; P=.040). To equate the 
groups on this variable (a potential confounding factor of other clini‐
cal and neuropsychological measures), the two BP- A participants with 
the longest duration of illness (58 and 57 years, respectively) were 
excluded, which eliminated the significant difference in duration of 
illness (BP- A, mean duration 24.8 years [SD=13.5 years] vs BP- P, 
22.4 years [SD=13.0 years]; t=1.80; df=377; P=.073). The results 
below, therefore, include 168 BP- A participants and 213 BP- P partici‐
pants, for a total of 381 participants diagnosed with BP. For compari‐
son purposes, we also performed the same analyses using the sample 
including these two participants, and the results were identical and 
thus are not reported here.
Continuous clinical variables included age of onset, duration of ill‐
ness (years), and medication load (described below). Ordinal variables 
(categories with increasing level of severity) were analyzed identically 
to continuous variables and included history of mixed episodes, his‐
tory of suicidal thoughts or behavior, history of substance abuse, and 
functional impact of illness (a global rating of the degree to which psy‐
chiatric illness has led to disability or inability to live independently). 
Total medication load was assessed using a protocol commonly used 
in the literature and fully described in a previous report; briefly, it in‐
volved coding psychiatric medications based on standardized dose 
equivalents and summing them to create a composite measure.16 
Medications were also coded and analyzed between groups according 
to type, including mood stabilizer, antipsychotic, antidepressant, and 
benzodiazepine. Categorical variables included first- degree relative 
with BP, chronicity of affective disorder, and presence of rapid cycling. 
Category labels for each clinical variable can be found in Figure 2.
To characterize the strength of the evidence in favor of the null hy‐
potheses, Bayes factors were calculated for each of the demographic, 
clinical, and neuropsychological comparisons using the R package 
“BayesFactor”.17 The Bayesian approach considers data using a ratio 
that contrasts the likelihood of the data fitting under the alternative 
hypothesis with the likelihood of fitting under the null hypothesis; this 
ratio is expressed as the Bayes factor.18 The distinct advantage of this 
approach over (or in addition to) traditional frequentist hypothesis 
testing is that it provides an estimate of the amount of evidence pres‐
ent in the data, facilitating the interpretation of P- values that may be 
approaching the selected cutoff for statistical significance.18 For these 
analyses, interpretation followed accepted guidelines where Bayes 
factors between 1 and 3 provide anecdotal evidence for the alterna‐
tive hypothesis, those between 3 and 10 provide substantial evidence, 
and those between 10 and 30 provide strong evidence; conversely, 
Bayes factors between 0.33 and 1 provide anecdotal evidence for the 
null hypothesis, those between 0.10 and 0.33 provide substantial ev‐
idence, and those between 0.03 and 0.10 provide strong evidence.18
3  | RESULTS
3.1 | Sample characteristics
Table 1 includes demographic and clinical characteristics of all par‐
ticipants. On average, participants with BP (n=403) were 41 years old 
with 15 years of education; the majority (65%) were women. Their 
mean age of onset was 18 years, with an average duration of illness 
of 23 years.
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3.2 | Phenomenology of psychosis
Figure 3 details the range and type of psychotic symptoms reported 
by participants with a confirmed history of psychosis (n=213; 53%). 
The majority of BP- P participants reported experiencing delusional 
ideation, with nearly half experiencing grandiose delusions. Less than 
half of BP- P participants experienced hallucinations in any modality. 
Relatively few BP- P participants endorsed traditional “first- rank” hal‐
lucinations of running commentary or two or more voices conversing.
3.3 | Comparisons among BP- A and BP- P 
participants
Demographically, there were no significant differences between 
groups on age, education, gender, age of onset, or medication load 
(all P>.152; Table 1). Examining classes of medications, BP- P partici‐
pants were more likely to be prescribed mood- stabilizing or antip‐
sychotic medication, although Bayes factors indicate only anecdotal 
evidence for higher rates; there were no differences between groups 
on prescription of antidepressant or benzodiazepine medication 
(Table 1).
In terms of clinical and functional variables, there were no sig‐
nificant differences on history of mixed episodes, history of suicidal 
thoughts or behaviors, chronicity of substance use, functional impact 
of illness, or first- degree family history of BP (all P>.070; Figure 4). 
The groups significantly differed on chronicity of affective disorder 
(χ2=11.34; df=2; P=.003; Figure 4), with a higher proportion of BP- A 
participants experiencing mood symptoms most of the time com‐
pared with BP- P participants. Presence of rapid cycling was also more 
prevalent among BP- A than BP- P participants (χ2=7.12; df=2; P=.028; 
Figure 4). Bayes factors also favored the null hypothesis for most com‐
parisons (Bayes factors ranging from 0.12 to 0.69; Figure 4); the Bayes 
factor for affective chronicity was 14.35, suggesting strong support 
for the hypothesis that the BP- A and BP- P groups differ, and the Bayes 
factor for presence of rapid cycling was 1.27, indicating anecdotal ev‐
idence that the groups differ (Figure 4).
Regarding neuropsychological functioning, there were no signifi‐
cant differences between BP- A and BP- P participants in any of the 
eight neuropsychological domains (all P>.059; Figure 1). Bayes factors 
ranged from 0.14 to 0.68, indicating anecdotal to substantial evidence 
for the null hypothesis (Figure 1).
4  | DISCUSSION
This study examined the phenomenology of psychosis in BP as well 
as demographic, clinical, and neuropsychological differences between 
people diagnosed with BP with and without a history of psychosis. 
F IGURE  1 Neuropsychological domain z- scores with standard error bars, t statistics, and Bayes factors for group comparisons. These  
z- scores were calculated using the mean and standard deviation of the healthy control (HC) participants enrolled in this study. The y- axis on 
the Bayes factor graph is on a log- scale. The measures comprising each domain included: auditory memory=California Verbal Learning Test, 
second edition21; visual memory=Rey- Osterrieth Complex Figure Test22; fine motor dexterity=Purdue Pegboard23; emotion processing=Facial 
Emotion Perception Test24,25; verbal fluency and processing speed=Controlled Oral Word Association Test letter and animal fluency,26 Wechsler 
Adult Intelligence Scale, third edition (WAIS- III) Digit Symbol,27 Stroop Color- Word Interference Test, color reading and word reading,28 and Trail 
Making Test, part B29; conceptual reasoning and set- shifting=Wisconsin Card Sorting Test30 and Parametric Go/No- Go Test mean accuracy31; 
processing speed with interference resolution=Trail Making Test, parts A and B,29 WAIS- III Digit Symbol,27 Stroop Color- Word Interference Test, 
interference condition,28 and Parametric Go/No- Go Test mean response time31; inhibitory control=Parametric Go/No- Go Test mean accuracy 
and mean response time31
22  |     BURTON eT al.
The prevalence of psychosis in this sample (53%) is similar to other 
published reports.4,11 The type and content of psychosis endorsed in 
this sample are also consistent with the BP literature, in that a large 
number of participants endorsed grandiose ideation and relatively 
few endorsed Schneiderian first- rank symptoms that are tradition‐
ally more evident in schizophrenia.4 For the most part, psychosis in 
F IGURE  2 Clinical and functional comparisons between affective- only bipolar disorder (BP- A) and bipolar disorder with a history of 
psychosis (BP- P). (A) History of mixed episodes. (B) History of suicidality. (C) History of substance abuse. (D) Functional impact of illness. (E) 
First- degree relative with bipolar disorder. (F) Chronicity of affective disorder. (G) Presence of rapid cycling [Colour figure can be viewed at 
wileyonlinelibrary.com]
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BP also tends to be mood congruent and of briefer duration than in 
schizophrenia. Such a qualitative difference in psychosis between BP 
and schizophrenia suggests that, experientially, psychotic symptoms 
may manifest differently in the context of a mood disorder vs a pri‐
mary psychotic disorder; that is, the experience of psychosis as part 
of broader psychopathology may not improve diagnostic specificity, 
although the content may offer a clue as to the primary etiology and 
in turn inform appropriate treatment planning. Clinicians may find this 
helpful when conducting cross- sectional diagnostic interviews and at‐
tempting to achieve the difficult task of distinguishing between BP 
and schizophrenia- spectrum disorder.
In general, and somewhat contrary to expectation, our analyses 
largely failed to find significant clinical or functional differences be‐
tween the groups. Consistent with Aminoff et al.,10 in the full sample 
BP- P participants were found to have shorter duration of illness than 
BP- A participants. The difference of 22 vs 25 years is not likely to be 
clinically significant, and because participants did not differ on current 
age or age of onset, it could simply reflect a sampling issue (i.e., individ‐
uals experiencing psychosis may have come to the attention of referral 
sources more swiftly than their counterparts without psychosis). The 
results also indicate that BP- A participants had more chronic affective 
symptoms and rapid cycling, consistent with a subtype of patients with 
primary mood burden (e.g., chronic or persistent depression rather than 
brief, episodic psychosis). The lack of significant differences in numerous 
demographic or illness burden variables is consistent with other studies 
finding minimal differences between BP- A and BP- P participants.11
In terms of neuropsychological functioning, surprisingly BP- A 
and BP- P participants did not differ on measures of auditory and 
visual memory, fine motor dexterity, emotion processing, or exec‐
utive functioning (verbal fluency and processing speed, processing 
speed with interference resolution, conceptual reasoning and set- 
shifting, and inhibitory control). It is not the case that this sample 
was unusually neuropsychologically intact, as the BP participants 
performed more poorly than healthy controls in all measured do‐
mains (z- scores<0). So, although BP participants with and without 
psychosis were more cognitively impaired relative to control partic‐
ipants, they did not significantly differ from each other. That is to 
say, in this sample the presence of psychosis was not associated 
F IGURE  3 Psychosis phenomenology among bipolar disorder 
with a history of psychosis (BP- P) participants (n=213) 
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TABLE  1 Demographic and clinical characteristics and comparisons between affective- only bipolar disorder (BP- A) and bipolar disorder 
with a history of psychosis (BP- P) participants
All BP (n=381) BP- A (n=168) BP- P (n=213)
t or χ2 df P BF
Mean (SD) or  
N (%)
Mean (SD) or  
N (%)
Mean (SD) or  
N (%)
Demographic variables
Age (years) 40.9 (13.0) 41.9 (13.7) 40.0 (12.4) 1.44 379 .152 0.31
Education (years) 15.2 (2.2) 15.0 (2.1) 15.3 (2.3) −1.13 371 .260 0.21
Male (%) 135 (35.4%) 53 (31.5%) 82 (38.5%) 1.98 1 .159 0.35
Clinical variables
Age of onset (years) 17.3 (7.0) 17.0 (6.7) 17.6 (7.3) −0.90 377 .367 0.17
Duration of illness (years) 23.5 (13.2) 24.8 (13.5) 22.4 (13.0) 1.80 377 .073 0.54
Total medication load 2.8 (2.1) 2.7 (1.9) 2.8 (2.1) −0.63 357 .531 0.14
Prescribed mood stabilizer (%) 242 (63.5%) 101 (60.1%) 141 (66.2%) 4.30 1 .038 1.44
Prescribed antipsychotic (%) 141 (37.0%) 54 (32.1%) 87 (40.8%) 4.88 1 .027 1.62
Prescribed antidepressant (%) 173 (45.4%) 86 (51.2%) 87 (40.8%) 3.55 1 .060 0.83
Prescribed benzodiazepine (%) 92 (24.1%) 42 (25.0%) 50 (23.5%) 0.03 1 .872 0.16
BF, Bayes factor; SD, standard deviation.
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with worse neuropsychological functioning. These findings conflict 
with the results of Bora et al.’s meta- analysis,9 but are in line with 
the results of other recently published work.10,12,13 As Porter et al. 
point out in their review,19 mixed results between studies may reflect 
methodological differences in the neuropsychological domains and 
measures included. For example, the battery used in this study and 
that in the Aminoff et al. study10 and Roux et al. study13 included 
only the California Verbal Learning Test as a measure of verbal mem‐
ory, while Bora et al.9 also included another measure of list- learning 
and memory, as well as two measures of story memory. Although 
Demmo et al.12 also included a measure of story memory and did 
not find significant differences, it is possible that some measures are 
more sensitive than others and that including more measures in a 
neuropsychological domain increases the ability to detect subtle dif‐
ferences between groups. Use of a more comprehensive and consis‐
tent neuropsychological battery in future studies (see Van Rheenen 
& Rossell, for example20) would facilitate comparisons across studies 
and help address the question of neuropsychological difference be‐
tween BP- A and BP- P more conclusively.
This study is not without limitations, the most significant of which 
is that clinical information was gathered historically from retrospective 
self- report during a diagnostic interview and only supplemented with 
medical records if available. Although this limitation is inherent in any 
clinical research involving retrospective clinical history- taking and di‐
agnosis, it introduces the possibility of recall bias and incomplete or 
inaccurate information. It is possible, therefore, that some participants 
were misclassified, which could cloud comparisons between groups. 
Longitudinal collection of clinical data (as is being done in the parent 
study) will be helpful to decrease reliance on retrospective report. 
Advanced longitudinal analyses such as trajectory analyses and longi‐
tudinal structural equation modeling are planned when the sample size 
of participants with 5- year data is sufficient to enable these methods 
to be applied. Furthermore, prospective follow- up would inform ques‐
tions of whether and how psychosis in BP interacts with clinical status 
and neuropsychological functioning over time. Future studies focusing 
on participants early in the course of illness may also help reduce this 
bias. Moreover, whether those with BP and a history of psychosis have 
impaired autobiographical memory or less insight into their symptoms 
is deserving of future investigation, because that could also contribute 
to potential recall bias and inaccurate information. In addition, mood 
state at the time of evaluation was not formally collected or quantified, 
so it is unknown whether current mood state could have affected the 
testing results. We also did not analyze information comparing mood- 
congruent vs mood- incongruent psychotic features, which may have 
F IGURE  4  t statistics, chi- square statistics, and Bayes factors for clinical comparisons between affective- only bipolar disorder (BP- A) and 
bipolar disorder with a history of psychosis (BP- P). 
Positive t values indicate BP- A>BP- P and vice versa. The y- axis of the Bayes factor graph is on a log- scale
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important implications for clinical prognosis and functional outcome; 
future studies would benefit from examining these features among in‐
dividuals with psychotic bipolar disorder. Further, this study is limited 
by characteristics of the sample; for example, these participants were 
outpatients with relatively high educational attainment. It is not clear 
whether these findings would generalize to inpatient samples or those 
with less education or lower socioeconomic status. Finally, it would 
be interesting to compare these findings to those in individuals diag‐
nosed with a primary psychotic disorder (i.e., schizoaffective disorder 
and schizophrenia), to enable finer grained analysis of the presence of 
psychosis vs the primacy of psychosis.
To our knowledge, this is the largest single study to date comparing 
demographic, clinical, functional, and neuropsychological features of in‐
dividuals diagnosed with BP with and without psychosis. Overall, these 
results do not support the clinical and anecdotal notion that BP with psy‐
chotic features represents a more “severe” illness than BP without a his‐
tory of psychosis. In general, the presence of psychosis does not appear 
to be associated with poorer clinical or functional outcomes, or suggest a 
greater degree of neuropsychological impairment. This is particularly in‐
triguing in that many individuals in the BP- A group were diagnosed with 
BP II, which is thought to be a milder form of BP and would contribute 
to the expectation that BP- A participants would demonstrate less severe 
clinical course and neuropsychological impairment. Ultimately, although 
the presence of psychotic symptoms in the acute phase of bipolar ill‐
ness can be distressing to patients and their families, and may require 
increased level of care or hospitalization for immediate management, it 
may not factor in to long- term prognosis or lead to more severe neuro‐
psychological deficits as much as clinical intuition would suggest.
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